Preimplantation embryonic developmental arrest (EDA) is a common cause of unexplained female infertility. Genetic factors are believed to be one of the primary causes contributing to EDA. In this study, we identify four novel compound heterozygous mutations in TLE6 and NLRP5, in two infertile female patients experiencing recurrent EDA, using whole‐exome sequencing. Functional analysis revealed that the two splicing mutations in TLE6 (c.541+2dupT) and NLRP5 (c.2957+4A>G) resulted in aberrant RNA splicing, leading to abnormal truncations of the corresponding proteins. In vitro experiments further validated that a missense mutation in NLRP5 led to increased mRNA and protein expression levels compared to wild type, when transfected into HEK293T cells. Immunofluorescence analysis confirmed the decay of the expression of TLE6 protein. Additionally, RNA sequencing results revealed significantly higher expression levels of some maternal genes in mutated embryos with TLE6 mutations, possibly suggesting the disrupted clearance of maternal mRNA and the failure of embryo genome activation. These results highlight the role of biallelic recessive effects associated with TLE6 and NLRP5 variants in embryonic development, thereby widening the scope of the genetic landscape.
Recurrent spontaneous abortion (RSA), characterized by the occurrence of three or more pregnancy losses prior to the 28th week of gestation, stands as a formidable challenge in the realm of assisted reproductive medicine, presenting significant difficulties in both clinical diagnosis and treatment. In recent years, there has been a discernible upward trend in the incidence of RSA, and its etiology is multifaceted and intricate. Pinpointing the root causes of RSA remains an arduous task that urgently demands resolution within the field of reproductive medicine. Through a comprehensive and in-depth analysis of the RSA-related case report, embryonic chromosomal abnormalities were identified as the highest-risk factor. Utilizing preimplantation genetic testing for aneuploidy (PGT-A) technology, an euploid blastocyst was selected for transfer, which led to successful pregnancy and healthy birth. This case holds significant reference value for the clinical treatment of RSA.
This study aimed to investigate the potential benefits of frozen testicular sperm and to retrospectively analyze the clinical pregnancy and live birth outcomes following intracytoplasmic injection of fresh or frozen testicular sperm. A total of 468 infertile couples undergoing intracytoplasmic sperm injection cycles utilizing either fresh or frozen testicular sperm extracted between January 2017 and December 2021 were included in this analysis. Participants were categorized into two groups: those utilizing fresh testicular sperm (n = 324) and those utilizing frozen testicular sperm (n = 144). Outcome measures encompassed fertilization rate, embryo development, clinical outcomes, and birth status of infants. Statistical analysis revealed no significant differences in 2PN fertilization rate, Day 3 (D3) available embryo rate, high‐quality embryo rate, blastocyst formation rate, clinical pregnancy rate, live birth rate, and preterm birth rate between the two groups. Although the preterm birth rate in the frozen testicular sperm group was lower compared to the fresh testicular sperm group, the difference was not statistically significant (5.6% vs. 15.1%). Notably, there were no discernible distinctions in clinical pregnancy and birth outcomes, as well as infant birth parameters, between the fresh and frozen testicular sperm groups. These findings suggest that frozen testicular sperm holds practical value and warrants consideration for clinical application.